收费全文 | 5650篇 |
免费 | 486篇 |
国内免费 | 44篇 |
耳鼻咽喉 | 69篇 |
儿科学 | 190篇 |
妇产科学 | 134篇 |
基础医学 | 607篇 |
口腔科学 | 142篇 |
临床医学 | 676篇 |
内科学 | 993篇 |
皮肤病学 | 65篇 |
神经病学 | 548篇 |
特种医学 | 248篇 |
外科学 | 863篇 |
综合类 | 136篇 |
一般理论 | 2篇 |
预防医学 | 704篇 |
眼科学 | 142篇 |
药学 | 330篇 |
中国医学 | 6篇 |
肿瘤学 | 325篇 |
2023年 | 55篇 |
2022年 | 33篇 |
2021年 | 199篇 |
2020年 | 93篇 |
2019年 | 158篇 |
2018年 | 186篇 |
2017年 | 130篇 |
2016年 | 121篇 |
2015年 | 156篇 |
2014年 | 184篇 |
2013年 | 246篇 |
2012年 | 317篇 |
2011年 | 321篇 |
2010年 | 147篇 |
2009年 | 159篇 |
2008年 | 267篇 |
2007年 | 263篇 |
2006年 | 210篇 |
2005年 | 240篇 |
2004年 | 213篇 |
2003年 | 185篇 |
2002年 | 149篇 |
2001年 | 135篇 |
2000年 | 156篇 |
1999年 | 119篇 |
1998年 | 58篇 |
1997年 | 43篇 |
1996年 | 61篇 |
1995年 | 44篇 |
1994年 | 58篇 |
1993年 | 59篇 |
1992年 | 82篇 |
1991年 | 92篇 |
1990年 | 82篇 |
1989年 | 83篇 |
1988年 | 89篇 |
1987年 | 68篇 |
1986年 | 70篇 |
1985年 | 56篇 |
1984年 | 62篇 |
1983年 | 62篇 |
1982年 | 50篇 |
1981年 | 39篇 |
1980年 | 37篇 |
1979年 | 60篇 |
1978年 | 57篇 |
1977年 | 29篇 |
1974年 | 28篇 |
1973年 | 32篇 |
1970年 | 29篇 |
Background
Syphilis is resurgent in many developed countries and still prevalent in developing nations. Current and future control campaigns would benefit from the development of a vaccine, but although promising vaccine candidates were identified among the putative surface-exposed integral outer membrane proteins of the syphilis spirochete, immunization experiments in the rabbit model using recombinant antigens have failed to fully protect animals upon infectious challenge. We speculated that such recombinant immunogens, purified under denaturing conditions from Escherichia coli prior to immunization might not necessarily harbor their original structure, and hypothesized that enhanced protection would result from performing similar immunization/challenge experiments with native antigens.Methods
To test our hypothesis, we engineered non-infectious Borrelia burgdorferi strains to express the tp0897 (tprK) and tp0435 genes of Treponema pallidum subsp. pallidum and immunized two groups of rabbits by injecting recombinant strains intramuscularly with no adjuvant. TprK is a putative integral outer membrane protein of the syphilis agent, while tp0435 encodes the highly immunogenic T. pallidum 17-kDa lipoprotein, a periplasmic antigen that was also shown on the pathogen surface. Following development of a specific host immune response to these antigens as the result of immunization, animals were challenged by intradermal inoculation of T. pallidum. Cutaneous lesion development was monitored and treponemal burden within lesions were assessed by dark-field microscopy and RT-qPCR, in comparison to control rabbits.Results
Partial protection was observed in rabbits immunized with B. burgdorferi expressing TprK while immunity to Tp0435 was not protective. Analysis of the humoral response to TprK antigen suggested reactivity to conformational epitopes.Conclusions
Immunization with native antigens might not be sufficient to obtain complete protection to infection. Nonetheless we showed that non-infectious B. burgdorferi can be an effective carrier to deliver and elicit a specific host response to T. pallidum antigens to assess the efficacy of syphilis vaccine candidates. 相似文献Background
Catheter ablation of ventricular tachycardia (VT) can reduce the burden of ventricular arrhythmia (VA) but its effect on health care utilization and costs after such therapy is poorly known. We sought to compare the rates of cardiovascular (CV)-related hospitalizations, survival, and health care costs in patients with recurrent VT treated either with VT ablation or with medical therapy.Methods
One-hundred implantable cardioverter-defibrillator patients with structural heart disease who underwent VT ablation were included. Propensity score-matched patients with recurrent VT treated with medical therapy were identified from a prospective registry of approximately 7000 de novo implantable cardioverter-defibrillator patients. Outcomes and costs were ascertained using health administrative databases.Results
Among patients who underwent VT ablation, the cumulative rates of VA-related hospitalizations were lower in the 2 years after their ablation procedure compared with the year before (rate ratio, 0.3; 95% confidence interval [CI], 0.22-0.43). Rates of CV-related hospitalization and hospitalization because of VA post index date were similar between the VT ablation and medical therapy groups (hazard ratio [HR], 0.94; 95% CI, 0.57-1.54 and HR, 1.04; 95% CI, 0.57-1.91, respectively). Health care costs in the VT ablation patients were not increased post-ablation compared with the medical management group. The risk of all-cause mortality was lower among patients in the VT ablation group relative to the medical therapy group (HR, 0.64; 95% CI, 0.4-0.99).Conclusions
Patients who underwent VT ablation experienced a significant reduction in their rate of VA-related hospitalizations. Patients treated with VT ablation had similar rates of CV-related hospitalization compared with those treated with medical therapy without increased health care-related costs. 相似文献2. To assess the potential for inadequate coverage for these two AO enzyme-mediated metabolites in nonclinical safety studies, given concerns due to differences in AO enzymes expression between preclinical species and humans, the human circulating levels of the two AO enzyme-mediated metabolites were predicted prospectively using in vitro and in vivo models. Both formation clearance and elimination clearance of the two metabolites were predicted based on in vitro to in vivo correlation and comparison with in vivo data from rats.
3. The result showed that the 4-OH metabolite of Compound A would account for less than 3% of the total drug-related exposure in human plasma, while the exposure to the 2-oxo metabolite would be relatively high (~70%).
4. The predicted human exposure levels for the two metabolites are in similar ranges as those observed in monkeys. These data taken together support the advancement to clinical development of Compound A. 相似文献